Chondroitin sulfate proteoglycan 4 (CSPG4) overexpression as an oncogenic driver and prognostic marker for unfavorable outcomes in hepatocellular carcinoma
CSPG4 overexpression serves as an oncogenic driver and independent predictor of poor survival in HCC. Combining CSPG4 expression with established clinical variables presents a more precise risk assessment tool for individuals with HCC after hepatectomy, offering new insights for personalized treatment strategies and outcome prediction in HCC.
Authors
- Changjie Ren
- Mierxiati Abudurexiti (ORCID: https://orcid.org/0000-0002-5909-6663)
- Tianyu Hong
- Feihu Yan (ORCID: https://orcid.org/0000-0003-4227-0757)
- Chao Wang (ORCID: https://orcid.org/0000-0001-5196-9426)
- Ling Zhang (ORCID: https://orcid.org/0000-0001-7542-1879)
- Hao Xiang (ORCID: https://orcid.org/0000-0003-4803-3314)
- Ming-Da Wang (ORCID: https://orcid.org/0009-0007-4739-9492)
Institutions
- University of Shanghai for Science and Technology (CN)
- Second Military Medical University (CN)
- Zunyi Medical University (CN)
- Changchun Observatory (CN)
- Changhai Hospital (CN)
- First People’s Hospital of Zunyi (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Shanghai Pudong New Area Gongli Hospital (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1186/s12957-025-04133-1
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 0.00